Department of Colorectal Surgery, Royal Marsden Hospital, Fulham Road, London, UK.
Colorectal Dis. 2012 Dec;14(12):1457-66. doi: 10.1111/j.1463-1318.2012.03005.x.
To determine the presence and duration of survival advantages was investigated for resection margin status (R0, R1 or R2) following surgery for locally recurrent rectal cancer (LRRC).
A systematic review of the literature was performed for studies comparing resection margin status for LRRC. Weighted mean differences and meta-analysis of hazard ratios were used as a measure of median and overall cumulative survival.
Twenty-two studies were included, providing outcome for 1460 patients undergoing surgery for LRRC. 57% underwent an R0 resection, 25% an R1 resection and 11% an R2 resection. The most commonly performed operations were abdominoperineal excision (35%), exenteration (23%) and anterior resection (21%). The range of median survival per resection margin was R0 28-92 months, R1 12-50 months, R2 6-17 months. Patients undergoing an R0 resection survived on average for 37.6 (95% confidence interval: 23.5-51.7) months longer than those undergoing R1 resection and 53.0 (31.2-74.8) months longer than those undergoing R2 resection. This correlated to a hazard ratio of 2.03 (1.73-2.38) for R0 vs R1 and 3.41 (2.21-5.25) for R0 vs R2. Patients undergoing R1 resection survived on average 13.3 (7.23-19.4) months longer than those undergoing R2 resection [hazard ratio of 1.68 (1.33-2.12)].
Patients undergoing R0 resection have the greatest survival advantage following surgery for recurrent rectal cancer. There is a survival advantage for R1 over R2 resection, but there may be no benefit of R2 resection over palliative treatment.
研究局部复发性直肠癌(LRRC)手术后的切缘状态(R0、R1 或 R2)对生存优势的存在和持续时间。
对比较 LRRC 切缘状态的研究进行了系统的文献回顾。使用加权平均差异和危险比的荟萃分析作为衡量中位和总累积生存的指标。
共纳入 22 项研究,为 1460 例接受 LRRC 手术的患者提供了结果。57%的患者行 R0 切除术,25%行 R1 切除术,11%行 R2 切除术。最常施行的手术为腹会阴切除术(35%)、前切除术(21%)和直肠前切除术(21%)。每种切缘状态的中位生存时间范围分别为 R0 28-92 个月、R1 12-50 个月、R2 6-17 个月。R0 组患者的平均生存时间比 R1 组长 37.6 个月(95%置信区间:23.5-51.7),比 R2 组长 53.0 个月(31.2-74.8)。这对应于 R0 与 R1 相比的危险比为 2.03(1.73-2.38),R0 与 R2 相比的危险比为 3.41(2.21-5.25)。R1 组患者的平均生存时间比 R2 组长 13.3 个月(7.23-19.4),危险比为 1.68(1.33-2.12)。
R0 切除术后的患者在复发性直肠癌手术后具有最大的生存优势。R1 切除比 R2 切除有生存优势,但 R2 切除与姑息治疗相比可能没有获益。